JPWO2021224913A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021224913A5
JPWO2021224913A5 JP2022566612A JP2022566612A JPWO2021224913A5 JP WO2021224913 A5 JPWO2021224913 A5 JP WO2021224913A5 JP 2022566612 A JP2022566612 A JP 2022566612A JP 2022566612 A JP2022566612 A JP 2022566612A JP WO2021224913 A5 JPWO2021224913 A5 JP WO2021224913A5
Authority
JP
Japan
Prior art keywords
seq
binding domain
acid sequences
amino acid
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525695A5 (https=
JP2023525695A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2021/050506 external-priority patent/WO2021224913A1/en
Publication of JP2023525695A publication Critical patent/JP2023525695A/ja
Publication of JP2023525695A5 publication Critical patent/JP2023525695A5/ja
Publication of JPWO2021224913A5 publication Critical patent/JPWO2021224913A5/ja
Pending legal-status Critical Current

Links

JP2022566612A 2020-05-04 2021-05-04 前駆体三重特異性抗体構築物及びその使用方法 Pending JP2023525695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063019443P 2020-05-04 2020-05-04
US63/019,443 2020-05-04
US202063026143P 2020-05-18 2020-05-18
US63/026,143 2020-05-18
PCT/IL2021/050506 WO2021224913A1 (en) 2020-05-04 2021-05-04 Precursor tri-specific antibody constructs and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023525695A JP2023525695A (ja) 2023-06-19
JP2023525695A5 JP2023525695A5 (https=) 2024-04-24
JPWO2021224913A5 true JPWO2021224913A5 (https=) 2024-04-24

Family

ID=76076399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566612A Pending JP2023525695A (ja) 2020-05-04 2021-05-04 前駆体三重特異性抗体構築物及びその使用方法

Country Status (11)

Country Link
US (1) US20230312753A1 (https=)
EP (1) EP4146695A1 (https=)
JP (1) JP2023525695A (https=)
KR (1) KR20230005952A (https=)
CN (1) CN116096754A (https=)
AU (1) AU2021267953A1 (https=)
BR (1) BR112022022369A2 (https=)
CA (1) CA3181963A1 (https=)
IL (1) IL297412A (https=)
MX (1) MX2022013876A (https=)
WO (1) WO2021224913A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3966250A4 (en) * 2019-05-07 2022-11-23 Immunorizon Ltd. PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US20240228626A1 (en) * 2021-05-04 2024-07-11 Immunorizon Ltd. Anti-nkg2d antibodies and uses thereof
CA3217716A1 (en) * 2021-05-04 2022-11-10 Oren Bogin Anti-5t4 antibodies and uses thereof
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
JP2025500845A (ja) * 2021-12-14 2025-01-15 ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Cd94/nkg2aヘテロ二量体ポリペプチドに結合する分子
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
TW202540188A (zh) * 2023-12-01 2025-10-16 比利時商艾伯霖克斯公司 精準活化的多肽

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
CN101484471B (zh) * 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
CN101319011B (zh) * 2007-06-04 2010-11-10 中国人民解放军军事医学科学院基础医学研究所 多型别hcv-e1表位复合免疫原及其编码基因与应用
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
PT2403935T (pt) 2009-03-04 2017-09-22 Univ Pennsylvania Composições compreendendo fatores angiogénicos e metedos para a sua utilização
JP5593641B2 (ja) 2009-06-26 2014-09-24 味の素株式会社 減塩飲食品用組成物
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
KR102047248B1 (ko) * 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014012085A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス,インコーポレイティド 抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2959463A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
AU2015323313B2 (en) 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
CA3011374A1 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
CN109476756B (zh) * 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CR20180453A (es) 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
WO2019164930A1 (en) * 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
EP3793607A1 (en) * 2018-05-15 2021-03-24 MedImmune Limited Treatment of cancer
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020084608A1 (en) * 2018-10-22 2020-04-30 Explore Bio 1 Ltd Precursor bispecific antibody constructs and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024020298A5 (https=)
JP2025160458A5 (https=)
JP2022177090A5 (https=)
JP2020510422A5 (https=)
JP2021522162A5 (https=)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2020516240A5 (https=)
JP2020501531A5 (https=)
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JPWO2019224717A5 (https=)
JP2023093753A5 (https=)
JP2024024114A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2025038088A5 (https=)
JP2021512652A5 (https=)
JP2020513759A5 (https=)
JPWO2022256563A5 (https=)
JPWO2021224913A5 (https=)
JPWO2023020621A5 (https=)
JPWO2020227457A5 (https=)
JPWO2020233589A5 (https=)
FI3681911T3 (fi) Ihmisen trombiinireseptori PAR4:ään sitoutuvia proteiineja
JPWO2021116337A5 (https=)
JPWO2022268192A5 (https=)